Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506488 | 0.96 | ALDH1A1 (0.47) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL818480 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL28542807 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL819768 | 0.80 | ALDH1A1 (0.56) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL8791767 | 0.78 | ALDH1A1 (0.45) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL2475898 | 0.78 | IDO1 (0.46) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL2478058 | 0.77 | KDM4E (0.56) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL6283017 | 0.77 | ALDH1A1 (0.52) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL987442 | 0.77 | IDO1 (0.62) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL3522023 | 0.76 | MAPT (0.55) | ALDH1A1KDM4EKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-11-26 | — | — | US | disclosed |
| US-9132129-B2 | Antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-09-15 | — | — | US | disclosed |
| US-9132129-B2 | Antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-09-15 | — | — | US | disclosed |
| US-9132129-B2 | Antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-09-15 | — | — | US | disclosed |
| EP-2640705-A2 | NOVEL ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2013-09-25 | — | — | EP | disclosed |
| US-20130245049-A1 | Novel Antiviral Compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245049-A1 | Novel Antiviral Compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245049-A1 | Novel Antiviral Compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-09-19 | — | — | US | disclosed |
| US-20090023767-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-01-22 | — | — | US | disclosed |
| US-20090023767-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-01-22 | — | — | US | disclosed |
| EP-1976523-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-05-15 | — | — | US | disclosed |
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-05-15 | — | — | US | disclosed |
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-05-15 | — | — | US | disclosed |
| EP-1835918-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007081572-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007081572-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2006074281-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245049-A1 | Novel Antiviral Compounds | MAVS, EIF2AK2, ZC3HAV1 | ALDH1A1 1414/4885KDM4E 2092/4885KMT2A 3816/4885 |
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, BUB1B | ALDH1A1 2612/4885KDM4E 1158/4885KMT2A 880/4885 |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ALDH1A1 1414/4885KDM4E 2092/4885KMT2A 3816/4885 |
| US-20090023767-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, BUB1B | ALDH1A1 3142/4885KDM4E 1025/4885KMT2A 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.